Our Newsletter


Categories


Bookmark and Share

AOR Curcumin 95 - 100 vcaps

Click to enlarge

Price:
Not Available
SKU:
AOR11004
Weight:
0.10 KGS
Rating:
( )
Availability:
Usually shipped within 1-2 days


Add to Wish List

Click the button below to add the AOR Curcumin 95 - 100 vcaps to your wish list.

Product Description

Curcumin•95 is a standardized extract of curcuminoid complex extracted from the South Indian spice turmeric (Curcuma longa Linn.). Research supports the wide-ranging health benefits of curcuminoids, especially curcumin, including antioxidant effects, modulation of the production of inflammatory signal molecules (prostanoids and leukotrienes), and inhibition of the growth of cells which have not properly differentiated or whose growth pattern is abnormal. Curcumin is also a key botanical extract in traditional Ayurvedic medicine.

100 Vegi-Caps AOR11004
100% Vegetarian

SUPPLEMENT FACTS:
Serving Size: 1 Capsule

    %DRI
Turmeric (Curcuma longa Linn.) Extract (95% Curcuminoids) 500mg *

     Typical Distribution/Distribution type:

   
Curcumin (diferuloylmethane) 365mg *
Demethoxycurcumin 80mg *
Bis-Demethoxycurcumin 10mg *
Other curcuminoids 20mg *

*Dietary Reference Intake not established.
Other ingredients: none. Capsule: hypromellose, sorbitol, silicon dioxide, water.

Note: Herbal extracts will naturally vary in color from one batch to another.

AOR guarantees that no ingredients not listed on the label have been added to the product. Contains no wheat, gluten, corn, nuts, dairy, soy, eggs, fish or shellfish.

Suggested Use
Take one to eight capsules per day, or as directed by a qualified health care practitioner.

Main Application
As reported by literature:
• Anti-oxidant.
• Anti-inflammatory.
• Gastro-intestinal effects.
• Cardiovascular effects.
• Lipid metabolism.
• Anti-bacterial/Anti-fungal.
• Anti-viral.
• Anti-tumor activity.

Source
Root.

Cautions
None.

Pregnancy/Nursing
No studies, best avoid.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.


Curcuma Longa is a perennial herb that belongs to the ginger family. The rhizome is extensively used for imparting color and flavor to food including curries. As a powder, called turmeric, it is also used for medicinal and religious ceremonies.
Chemistry

Curcuma longa rhizomes yield about 8% essential oils and 10% fatty oil. Three major constituents have been identified:
(1.) Curcumin (diferuloyl methane)
(2.) Curcumin methane.
(3.) Di-hydroxy cinnamoyl methane.

The volatile oils contain cineol, camphor and linalool and are probably responsible for the antispasmodic activity. Borneol is present in the essential oil fraction and is largely responsible for the digestion-improving properties.

Pharmacological Properties
The benefits of Curcuma longa have been extensively researched, especially by Indian scientists.

1. Antioxidant
Numerous studies have shown that the various constituents of curcuma longa posses potent antioxidant properties. The ability of cucuminoids to reduce hydroxyl and peroxyl free radicals is well documented. Sharma reported curcumin to be an effective agent against lipid peroxidation.

2. Anti-inflammatory
The Central Drug Research Institute in India found curcumin to be the major constituent responsible for the anti-inflammatory activity. The classical model for studying acute effects of anti-inflammatory agents is to test their inhibitory action on the development of rat paw edema - the exudative phase of inflammation - induced, for instance, by the local injection of carrageenins. Thus inflammation is thought to be in part due to the action of prostaglandin derivative from arachidonic acid metabolism. A detailed evaluation of curcumin as a potential non-steroidal anti-inflammatory agent by Srimal and Dhawan found curcumin to be highly effective after oral administration. Curcumin was effective in other models of inflammation including granuloma, pouch, cotton pellet, formalin-induced, and Freund's adjuvant.

The mechanism of anti-inflammatory action of curcumin is not yet known. Some researchers found curcumin to be less effective in adrenalectomized rats, suggesting a participation of corticoidal steroids, while others did not observe any effect of curcumin salts on steroid release from the adrenal cortex. Recently, another, more specific in-vitro method has been developed which allows the study of the inhibitory mechanism of potential drugs. By using rat peritoneal neutrophilis, curcumin was tested for the direct effect on the 5-lipooxygenase activities. Another study found that curcumin was able to inhibit the production of pro-inflammatory mediators in microglial cells that had been stimulated to mount an inflammatory response. Microglial cells are activated after brain injuries and produce proinflammatory mediators and neurotoxic compounds. Curcumin decreased the production of these compounds, apparently by blocking NF-kB, a protein signal in the pathway that leads to their production. The overexpression of pro-inflammatory cytokines contributes to diseases such as Alzheimer's, cerebral ischemia and multiple sclerosis. The ability of curcumin to decrease inflammation presents an approach to slow the progression of these diseases.

3. Gastro-intestinal effects
Curcumin increases mucin content, thereby protecting the gastric mucosa against irritants. Controversial data exist regarding an anti-ulcerogenic activity of curcumin. Some researchers found a protective effect of curcumin against histamine-induced gastric ulceration, while others reported an ulcerogenic effect of curcumin.

Curcumin also possesses anti-spasmodic properties. Curcumin showed liver protective effects against carbon tetrachloride, D-Galactosamine and peroxide induced cytotoxicity. Curcumin increased bile acid production in dogs and rats.

4. Cardiovascular effects
A sharp and transient hypotensive effect of curcumin was reported in dogs. Curcumin also inhibited collagen and adrenaline-induced aggregation of platelets but did not affect prostacyclin (PGI2) synthesis.

5. Lipid metabolism
Rao and co-workers reported that rats fed with curcumin and cholesterol in their diet had only half to one-third of the serum and liver cholesterol levels compared to the controlled groups receiving cholesterol alone.

6. Anti-bacterial/Anti-fungal
Curcumin inhibited growth of most organisms including: Staph aureus, Streptococci, lactobacilli, corynebacterium, Baccilus aureus, and micrococcus pyogenes. The crude ether and chloroform extracts of curcuma longa showed fungistatic activity against several dermatophytes as well as anti-amoebic activity against Entamoeba histolytica.

7. Anti-viral
A 1993 study showed curcumin as an effective ally in the treatment against HIV. Curcumin was effective in inhibiting the replication of HIV in both acutely infected and chronically infected cells.

8. Anti-tumor activity
The anti-tumor activity of various extracts of curcuma longa has been remarked by several researchers. Topical application of curcumin inhibited the number of TPA-induced tumors by as much as 98%!! Curcumin was found to be a selective and non-competitive inhibitor of phosphorylase kinase.

References

Jin C, Lee J, Park C, Choi Y, Kim G. (2007). "Curcumin attenuates the release of pro-inflammatory cytokines in lipopolysaccaride-stimulated BV2 microglia." Acta Pharmacol Sin; 28(10):2645-165

Srivastava, R. and Srimal R.C. (1985). "Modification of certain inflammation-induced biochemical changes by curcumin". Ind. J. Med. Res; 81:215-223.

Reddy, S and Agarwal, B (1993). "Curcumin as a non-competitive and selective inhibitor of phosphorylase kinase". FEBS 341:19-22.

Deodhar, S.D et al (1980). "Preliminary study on antirheumatic activity of curcumin (diferuloyl methane)". Ind. J. Med; 71:632-634.

Srimal R.C. and Shawan, B.N, (1973). "Pharmacology of curcumin, a non-steroidal anti-inflammatory agent". J. Clin Pharmacol Ther Toxicol; 24:651-654.

Ammon, IF.P.T. et al (1993). "Mechanism of anti-inflammatory actions of curcumin and boswellic acids". J Ethanophamacology; 38:113-119.

Ammon, IF.P.T. et al (1992). "Curcumin: A potent inhibitor of leukotriene B4 formation in rat peritoneal polymorphonuclear neutrophils." Planta Media; 58: 226-239.

Safayhi H. et al (1992). "Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase". J. Pharmacol. Exp. Therap; 261:1143-1146.


Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy.
Am J Hum Genet. 2007 Sep;81(3):438-53.
Khajavi M, Shiga K, Wiszniewski W, He F, Shaw CA, Yan J, Wensel TG, Snipes GJ, Lupski JR.

Mutations in myelin genes cause inherited peripheral neuropathies that range in severity from adult-onset Charcot-Marie-Tooth disease type 1 to childhood-onset Dejerine-Sottas neuropathy and congenital hypomyelinating neuropathy. Many myelin gene mutants that cause severe disease, such as those in the myelin protein zero gene (MPZ) and the peripheral myelin protein 22 gene (PMP22), appear to make aberrant proteins that accumulate primarily within the endoplasmic reticulum (ER), resulting in Schwann cell death by apoptosis and, subsequently, peripheral neuropathy. We previously showed that curcumin supplementation could abrogate ER retention and aggregation-induced apoptosis associated with neuropathy-causing MPZ mutants. We now show reduced apoptosis after curcumin treatment of cells in tissue culture that express PMP22 mutants. Furthermore, we demonstrate that oral administration of curcumin partially mitigates the severe neuropathy phenotype of the Trembler-J mouse model in a dose-dependent manner. Administration of curcumin significantly decreases the percentage of apoptotic Schwann cells and results in increased number and size of myelinated axons in sciatic nerves, leading to improved motor performance. Our findings indicate that curcumin treatment is sufficient to relieve the toxic effect of mutant aggregation-induced apoptosis and improves the neuropathologic phenotype in an animal model of human neuropathy, suggesting a potential therapeutic role in selected forms of inherited peripheral neuropathies.


Curcumin protects against acute liver damage in the rat by inhibiting NF-kappaB, proinflammatory cytokines production and oxidative stress.
Biochim Biophys Acta. 2007 Jun;1770(6):989-96. Epub 2007 Feb 22.
Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG, Muriel P.

Curcumin, an anti-inflammatory and antioxidant compound, was evaluated for its ability to suppress acute carbon tetrachloride-induced liver damage. Acute hepatotoxicity was induced by oral administration of CCl(4) (4 g/kg, p.o.). Curcumin treatment (200 mg/kg, p.o.) was given before and 2 h after CCl(4) administration. Indicators of necrosis (alanine aminotransferase) and cholestasis (gamma-glutamyl transpeptidase and bilirubins) resulted in significant increases after CCl(4) intoxication, but these effects were prevented by curcumin treatment. As an indicator of oxidative stress, GSH was oxidized and the GSH/GSSG ratio decreased significantly by CCl(4), but was preserved within normal values by curcumin. In addition to its antioxidants properties, curcumin is capable of preventing NF-kappaB activation and therefore to prevent the secretion of proinflammatory cytokines. Therefore, in this study we determined the concentrations of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) mRNA, and NF-kappaB activation. CCl(4)-administered rats depicted significant increases in TNF-alpha, IL-1beta, and IL-6 production, while curcumin remarkably suppressed these mediators of inflammation in liver damage. These results were confirmed by measuring TNF-alpha, and IL-1beta protein production using Western Blot analysis. Accordingly, these proteins were increased by CCl(4) and this effect was abolished by curcumin. Administration of CCl(4) induced the translocation of NF-kappaB to the nucleus; CCl(4) induced NF-kappaB DNA binding activity was blocked by curcumin treatment. These findings suggest that curcumin prevents acute liver damage by at least two mechanisms: acting as an antioxidant and by inhibiting NF-kappaB activation and thus production of proinflammatory cytokines.


Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP.
Acta Pharmacol Sin. 2007 Mar;28(3):423-30.
Zhang HN, Yu CX, Zhang PJ, Chen WW, Jiang AL, Kong F, Deng JT, Zhang JY, Young CY.

Aim: To elucidate the effect and the mechanisms of curcumin on the expression of the human homeobox gene NKX3.1 in the prostate cancer cell LNCaP.
Methods: The expression change of NKX3.1 in cells incubated with varying concentrations of curcumin was observed by Western blotting and RT-PCR. A dual luciferase reporter assay was used to test the effect of curcumin on the activity of the NKX3.1 1040 bp promoter. Curcumin-treated cells disposed to a designated amount of androgen analog R1881 and the androgen receptor (AR) antagonist flutamide, then the expression of NKX3.1 or the activity of the NKX3.1 promoter were investigated by Western blotting or reporter gene assay, respectively. Finally, Western blotting and electrophoretic mobility shift assay were performed to demonstrate the effect of curcumin on the expression of AR and its binding activity to the androgen response element (ARE).
Results: Curcumin downregulated the expression of NKX3.1 and the activity of the NKX3.1 1040 bp promoter in LNCaP cells. R1881 increased the expression of NKX3.1, and the AR antagonist flutamide decreased the expression of NKX3.1 in LNCaP cells, while curcumin could inhibit androgen-AR mediated induction of NKX3.1 expression. Curcumin decreased the expression of AR and the binding activity to ARE directly.
Conclusion: Curcumin could downregulate NKX3.1 expression in LNCaP cells. It could also inhibit the androgen-AR mediated induction of NKX3.1 expression by downregulating AR expression and blocking its DNA binding activity.


Phase I Clinical Trial of Oral Curcumin
Clinical Cancer Research 2004;10:6847-6854.
Sharmal RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt R, Marczylol TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ and Steward WP.

Curcumin, a polyphenolic antioxidant derived from a dietary spice, exhibits anticancer activity in rodents and in humans. Its efficacy appears to be related to induction of glutathione S-transferase enzymes, inhibition of prostaglandin E2 (PGE2) production, or suppression of oxidative DNA adduct (M1G) formation. We designed a dose-escalation study to explore the pharmacology of curcumin in humans. Fifteen patients with advanced colorectal cancer refractory to standard chemotherapies consumed capsules compatible with curcumin doses between 0.45 and 3.6 g daily for up to 4 months. Levels of curcumin and its metabolites in plasma, urine, and feces were analyzed by high-pressure liquid chromatography and mass spectrometry. Three biomarkers of the potential activity of curcumin were translated from preclinical models and measured in patient blood leukocytes: glutathione S-transferase activity, levels of M1G, and PGE2 production induced ex vivo. Dose-limiting toxicity was not observed. Curcumin and its glucuronide and sulfate metabolites were detected in plasma in the 10 nmol/L range and in urine. A daily dose of 3.6 g curcumin engendered 62% and 57% decreases in inducible PGE2 production in blood samples taken 1 hour after dose on days 1 and 29, respectively, of treatment compared with levels observed immediately predose (P < 0.05). A daily oral dose of 3.6 g of curcumin is advocated for Phase II evaluation in the prevention or treatment of cancers outside the gastrointestinal tract. PGE2 production in blood and target tissue may indicate biological activity. Levels of curcumin and its metabolites in the urine can be used to assess general compliance.


Mechanism of antiinflammatory actions of curcumine and boswellic acids.
J Ethnopharmacol 1993 Mar; 38(2-3): 113-9.
Ammon HP, Safayhi H, Mack T, Sabieraj J.

Curcumine from Curcuma longa and the gum resin of Boswellia serrata, which were demonstrated to act as anti-inflammatories in in vivo animal models, were studied in a set of in vitro experiments in order to elucidate the mechanism of their beneficial effects. Curcumine inhibited the 5-lipoxygenase activity in rat peritoneal neutrophils as well as the 12-lipoxygenase and the cyclooxygenase activities in human platelets. In a cell free peroxidation system curcumine exerted strong antioxidative activity. Thus, its effects on the dioxygenases are probably due to its reducing capacity. Boswellic acids were isolated from the gum resin of Boswellia serrata and identified as the active principles. Boswellic acids inhibited the leukotriene synthesis via 5-lipoxygenase, but did not affect the 12-lipoxygenase and the cyclooxygenase activities. Additionally, boswellic acids did not impair the peroxidation of arachidonic acid by iron and ascorbate. The data suggest that boswellic acids are specific, non-redox inhibitors of leukotriene synthesis either interacting directly with 5-lipoxygenase or blocking its translocation.


Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase.
J Pharmacol Exp Ther 1992 Jun; 261(3): 1143-6.
Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP.

Isomers (alpha- and beta-) of boswellic acids (BAs), 11-keto-beta-BA and their acetyl derivatives were isolated from the gum resin of Boswellia serrata. BA and derivatives concentration dependently decreased the formation of leukotriene B4 from endogenous arachidonic acid in rat peritoneal neutrophils. Among the BAs, acetyl-11-keto-beta-BA induced the most pronounced inhibition of 5-lipoxygenase (5-LO) product formation with an IC50 of 1.5 microM. In contrast to the redox type 5-LO inhibitor nordihydroguaiaretic acid, BA in concentrations up to 400 microM did not impair the cyclooxygenase and 12-lipoxygenase in isolated human platelets and the peroxidation of arachidonic acid by Fe-ascorbate. The data strongly suggest that BAs are specific, nonreducing-type inhibitors of the 5-LO product formation either interacting directly with the 5-LO or blocking its translocation.


Inhibitory effect of dietary curcumin on skin carcinogenesis in mice.
Cancer Lett 1997 Jun 24; 116(2): 197-203.
Limtrakul P, Lipigorngoson S, Namwong O, Apisariyakul A, Dunn FW.

Laboratory animal model studies have suggested that curcumin may play an important role in inhibiting the process of carcinogenesis. Curcumin, the yellow pigment that is obtained from rhizomes of the plant Curcuma longa Linn (Family Zingiberaceae), is commonly used as a spice and food coloring agent. The present study was designed to investigate the chemopreventive action of dietary curcumin on 7,12-dimethylbenz[a]anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted skin tumor formation in male Swiss ablino mice. At 6 weeks of age, groups of animals were fed the standard (modified AIN-76 A) diet or a diet containing 1% curcumin. At 8 weeks of age, all animals, except those in the vehicle (acetone)-treated groups, received 100 microg of DMBA dissolved in 100 microl of acetone in a single application to the skin of the back. From 1 week after DMBA application, tumor promoter (2.5 microg of TPA dissolved in 100 microl of acetone) was applied to the same areas on mouse skin twice a week for 26 weeks. All groups continued on their respective dietary regimen until the termination of the experiment. The results indicate that dietary administration of curcumin significantly inhibited the number of tumors per mouse (P < 0.05) and the tumor volume (P < 0.01). The percentage of tumor-bearing mice tended to be lower in the mice on the curcumin diet than those on the standard diet. There was no difference in growth between mice of the standard and 1% curcumin groups. The results indicate the safety and the anti-carcinogenic effect of curcumin in mice.


Turmeric: A Brief Review of Medicinal Properties
Fitoterapia 1997; 68(6): 483-493.
Srimal RC

Turmeric has been attributed a number of medicinal properties in the traditional system of medicine and its internal as well local use has been advocated. The major claims have been for use as antiseptic, cure for poisoning, eliminating body waste products, for dyspesia, respiratory disorders and cure for a number of skin diseases including promotion of wound healing. Recent studies have confirmed some of the older claims and brought out several new useful properties. Curcumin, curcuminoids and essential oils are the major active constituents. The main activities have been found to be anti-inflammatory, hepatoprotective, antimicrobial, wound healing, anticancer, antitumor and antiviral. Discovery of antiviral properties in curcumin, particularly against HIV, is interesting and needs proper evaluation. The review highlights some of the newer researchers, which may explain the multifaceted activity of this natural product. Different extracts of turmeric and also curcumin have been tried clinically in several diseased conditions with gratifying results.



Find Similar Products by Tag

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Recent News







Discounts, Wholesale, Buy

Your Shopping Cart


You just added this product to your cart:

Other Products in Your Shopping Cart:


Shipping:
Handling:
Subtotal: CAD$ 0.00

View your entire cart

You Recently Viewed...